Tags

Type your tag names separated by a space and hit enter

Effect of montelukast on exhaled nitric oxide and nonvolatile markers of inflammation in mild asthma.
Chest. 2003 Oct; 124(4):1334-40.Chest

Abstract

STUDY OBJECTIVES

Leukotriene receptor antagonists appear to exert anti-inflammatory activity in asthma. We undertook the present study to evaluate the effect of montelukast on levels of exhaled nitric oxide (ENO) and two inflammatory markers, hydrogen peroxide (H(2)O(2)), and cysteinyl leukotrienes (cys-LTs), in the exhaled breath condensate of subjects with mild asthma.

PATIENTS

Twenty stable subjects with mild asthma (15 women and 5 men; mean [+/- SD] age, 34.8 +/- 12.6 years) were included in the study.

INTERVENTION

A 1-week run-in period was followed by 2 weeks of treatment (with montelukast or placebo) that was administered in randomized, double-blind, crossover fashion. One week of washout followed each treatment arm.

RESULTS

Montelukast significantly reduced the levels of ENO from baseline (median, 52.5 parts per billion [ppb]; 25th to 75th percentile, 37.8 to 101.8 ppb) during the entire treatment period (ie, day 1 to day 14), with the effect measurable as early as day 1 (median, 45.9 ppb; 25th to 75th percentile, 29.3 to 92.5 ppb) and with the maximal effect being observed on day 7 (median, 35.7 ppb; 25th to 75th percentile, 27.6 to 66.6 ppb). The levels of ENO did not change significantly with placebo therapy. Montelukast improved symptom score and reduced peak expiratory flow (PEF) variability. Changes in PEF variability correlated positively with changes in ENO (r = 0.46; p = 0.04). No significant changes in FEV(1) or concentration of H(2)O(2) in the exhaled breath condensate were observed. Levels of cys-LTs were undetectable in the exhaled breath condensate.

CONCLUSIONS

We concluded that montelukast reduces the levels of ENO in patients with mild asthma, a finding that is compatible with an anti-inflammatory effect of montelukast, and that ENO appears to be more sensitive in detecting this effect than FEV(1) and H(2)O(2) levels in the exhaled breath condensate.

Authors+Show Affiliations

Asthma & Airway Centre of the Toronto Western Hospital, Division of Respiratory Medicine, University Health Network, University of Toronto, Toronto, ON, Canada.No affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info available

Pub Type(s)

Clinical Trial
Journal Article
Randomized Controlled Trial
Research Support, Non-U.S. Gov't

Language

eng

PubMed ID

14555563

Citation

Sandrini, Alessandra, et al. "Effect of Montelukast On Exhaled Nitric Oxide and Nonvolatile Markers of Inflammation in Mild Asthma." Chest, vol. 124, no. 4, 2003, pp. 1334-40.
Sandrini A, Ferreira IM, Gutierrez C, et al. Effect of montelukast on exhaled nitric oxide and nonvolatile markers of inflammation in mild asthma. Chest. 2003;124(4):1334-40.
Sandrini, A., Ferreira, I. M., Gutierrez, C., Jardim, J. R., Zamel, N., & Chapman, K. R. (2003). Effect of montelukast on exhaled nitric oxide and nonvolatile markers of inflammation in mild asthma. Chest, 124(4), 1334-40.
Sandrini A, et al. Effect of Montelukast On Exhaled Nitric Oxide and Nonvolatile Markers of Inflammation in Mild Asthma. Chest. 2003;124(4):1334-40. PubMed PMID: 14555563.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Effect of montelukast on exhaled nitric oxide and nonvolatile markers of inflammation in mild asthma. AU - Sandrini,Alessandra, AU - Ferreira,Ivone M, AU - Gutierrez,Carlos, AU - Jardim,Jose R, AU - Zamel,Noe, AU - Chapman,Kenneth R, PY - 2003/10/14/pubmed PY - 2003/12/3/medline PY - 2003/10/14/entrez SP - 1334 EP - 40 JF - Chest JO - Chest VL - 124 IS - 4 N2 - STUDY OBJECTIVES: Leukotriene receptor antagonists appear to exert anti-inflammatory activity in asthma. We undertook the present study to evaluate the effect of montelukast on levels of exhaled nitric oxide (ENO) and two inflammatory markers, hydrogen peroxide (H(2)O(2)), and cysteinyl leukotrienes (cys-LTs), in the exhaled breath condensate of subjects with mild asthma. PATIENTS: Twenty stable subjects with mild asthma (15 women and 5 men; mean [+/- SD] age, 34.8 +/- 12.6 years) were included in the study. INTERVENTION: A 1-week run-in period was followed by 2 weeks of treatment (with montelukast or placebo) that was administered in randomized, double-blind, crossover fashion. One week of washout followed each treatment arm. RESULTS: Montelukast significantly reduced the levels of ENO from baseline (median, 52.5 parts per billion [ppb]; 25th to 75th percentile, 37.8 to 101.8 ppb) during the entire treatment period (ie, day 1 to day 14), with the effect measurable as early as day 1 (median, 45.9 ppb; 25th to 75th percentile, 29.3 to 92.5 ppb) and with the maximal effect being observed on day 7 (median, 35.7 ppb; 25th to 75th percentile, 27.6 to 66.6 ppb). The levels of ENO did not change significantly with placebo therapy. Montelukast improved symptom score and reduced peak expiratory flow (PEF) variability. Changes in PEF variability correlated positively with changes in ENO (r = 0.46; p = 0.04). No significant changes in FEV(1) or concentration of H(2)O(2) in the exhaled breath condensate were observed. Levels of cys-LTs were undetectable in the exhaled breath condensate. CONCLUSIONS: We concluded that montelukast reduces the levels of ENO in patients with mild asthma, a finding that is compatible with an anti-inflammatory effect of montelukast, and that ENO appears to be more sensitive in detecting this effect than FEV(1) and H(2)O(2) levels in the exhaled breath condensate. SN - 0012-3692 UR - https://www.unboundmedicine.com/medline/citation/14555563/Effect_of_montelukast_on_exhaled_nitric_oxide_and_nonvolatile_markers_of_inflammation_in_mild_asthma_ L2 - https://linkinghub.elsevier.com/retrieve/pii/S0012-3692(16)48676-9 DB - PRIME DP - Unbound Medicine ER -